Release summary: Molecular Instruments launches fully ambient-temperature HCR (TM) Pro RNA-ISH on the BOND-III, marking a new generation of clinical-grade RNA-ISH designed to reduce heat-driven ...

The firm originally submitted a new drug application seeking approval of the drug in 2016, which was rejected, and, in 2024, resubmitted an application.

In a major blow to vaccine development, the FDA said it will not review Moderna’s application for the first mRNA-based flu shot.

Wave Life Sciences is rated Hold, reflecting high pipeline potential but significant clinical, regulatory, and commercial ...

A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across ...

A protein that quietly suppresses tooth growth may hold the key to regrowing teeth in adults, according to a line of research that has moved from mouse models to the doorstep of human clinical trials.

WOBURN, MA, UNITED STATES, February 9, 2026 /EINPresswire.com/ -- Powered by AFA‑enabled workflows that deliver ...

This mini-review synthesises evidence showing that adenosine-to-inosine RNA editing plays an important regulatory role in cardiovascular development, cellular homeostasis, and disease biology. It ...

Lilac Biosciences, a biotechnology company spun out of the Giuliani RNA Center at Brown University, developing quantitative RNA-based analytical tools, announced a research collaboration with Soin ...

Rejecting a recently developed Moderna flu vaccine, the HHS continues to distance itself from mRNA research and development.

Researchers have developed a near-single-cell resolution spatial transcriptomic approach to study developmentally regulated RNA processes.

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...